<DOC>
	<DOCNO>NCT00775242</DOCNO>
	<brief_summary>During menopause woman 's body slowly produce less hormone estrogen progesterone . Lower hormone level menopause may lead hot flash , vaginal dryness osteoporosis . To help problem , woman often give estrogen estrogen progestin . The purpose study ass compare efficacy safety three dos estradiol progesterone treatment climacteric symptom</brief_summary>
	<brief_title>Efficacy Safety Estradiol Progesterone Microspheres Treatment Climacteric Symptoms .</brief_title>
	<detailed_description>Different formulation estrogens progestin use treatment climacteric symptom , however date formulation completely satisfactory . Our company develop new technology preparation control release bioerodible non-polymeric microspheres , microspheres capable deliver dos estradiol ( E ) progesterone ( P ) level appropriate Hormonal Replacement Therapy ( HRT ) order relieve climacteric symptom . Non clinical clinical study conduct aim assess pharmacokinetics microspheres , several dos progesterone estradiol . Results show sustain plasma profile steroid within therapeutic range several day attain . On basis , new efficacy safety study go conduct purpose assess define appropriate dos estradiol progesterone HRT climacteric symptom . Three different dos progesterone estradiol ( 0.5 mg E + 15 mg P vs 1 mg E + 20 mg P vs 1 mg E + 30 mg P ) compare term efficacy safety treat climacteric symptom healthy postmenopausal woman .</detailed_description>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Age 40 65 year . Perimenopausal subject : Women show spontaneous amenorrhea last 11 month . Postmenopausal subject : Women le 12 consecutive month amenorrhea FSH &gt; 40 mIU/mL Subjects show vasomotor symptom , less 3 hot flash day le 21 hot flash week Healthy subject determine basis satisfactory complete clinical history , clinical laboratory test , cervical cytology , endometrium biopsy vaginal pelvic ultrasonography . Subjects receive hormonal treatment . Subjects background endometrial hyperplasia endometrial cancer . Subjects endometrial hyperplasia endometrial cancer assess endometrial biopsy . Perimenopausal subject background abnormal uterine bleeding unless Principal Clinical Investigator consider abnormality secondary menopausal condition . Subjects hypersensitivity medicament . Subjects direct family background breast cancer . Subjects background cardiovascular disease , renal , hepatic , metabolic , gastrointestinal , neurologic , endocrine , gynecologic disease include dysfunctional uterine bleeding , cervico uterine dysplasia , cancer , anemia , emotional disorder , chronic degenerative disorder could affect participation study . Subjects require medicament course study unless Principal Clinical Investigator consider pharmacological interaction .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Hormone Replacement Therapy</keyword>
	<keyword>Microspheres</keyword>
	<keyword>Progesterone</keyword>
	<keyword>Estradiol</keyword>
	<keyword>Hot flash</keyword>
</DOC>